Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
CMOs showed an increasing reluctance to take on debt in 2022
This transformation will enable GE HealthCare to build a strong foundation for business growth
Subscribe To Our Newsletter & Stay Updated